- Home
- DNTH vs PHAT Comparison
DNTH vs PHAT Comparison
Compare DNTH & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- PHAT
- Stock Information
- Founded
- DNTH 2015
- PHAT 2018
- Country
- DNTH United States
- PHAT United States
- Employees
- DNTH N/A
- PHAT N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- DNTH Health Care
- PHAT Health Care
- Exchange
- DNTH Nasdaq
- PHAT Nasdaq
- Market Cap
- DNTH 651.8M
- PHAT 640.9M
- IPO Year
- DNTH N/A
- PHAT 2019
- Fundamental
- Price
- DNTH $20.74
- PHAT $10.24
- Analyst Decision
- DNTH Strong Buy
- PHAT Strong Buy
- Analyst Count
- DNTH 8
- PHAT 5
- Target Price
- DNTH $53.00
- PHAT $16.40
- AVG Volume (30 Days)
- DNTH 326.6K
- PHAT 1.1M
- Earning Date
- DNTH 08-07-2025
- PHAT 08-07-2025
- Dividend Yield
- DNTH N/A
- PHAT N/A
- EPS Growth
- DNTH N/A
- PHAT N/A
- EPS
- DNTH N/A
- PHAT N/A
- Revenue
- DNTH $4,854,000.00
- PHAT $114,039,000.00
- Revenue This Year
- DNTH N/A
- PHAT $194.40
- Revenue Next Year
- DNTH N/A
- PHAT $103.23
- P/E Ratio
- DNTH N/A
- PHAT N/A
- Revenue Growth
- DNTH 17.87
- PHAT 1049.82
- 52 Week Low
- DNTH $13.37
- PHAT $2.21
- 52 Week High
- DNTH $32.27
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- DNTH 53.56
- PHAT 63.28
- Support Level
- DNTH $18.08
- PHAT $8.03
- Resistance Level
- DNTH $21.18
- PHAT $11.19
- Average True Range (ATR)
- DNTH 1.50
- PHAT 0.63
- MACD
- DNTH -0.10
- PHAT 0.16
- Stochastic Oscillator
- DNTH 59.38
- PHAT 69.98
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.